Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen to fuel tumors and maximize the therapeutic effects of radiotherapy.

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

LinkGevity is a biotechnology company specializing in drug discovery, with a focus on longevity and age-related diseases. It operates an AI-powered platform designed to expedite the development of life-saving medications. By combining AI and pharmaceutical expertise, the company analyzes extensive datasets to predict and identify promising drug candidates, aiming to extend healthy lifespan and bring innovative treatments to market more swiftly.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

New Wave Biotech specializes in developing software that optimizes downstream processes for synthetic biology products, particularly in the alternative protein sector. The company's platform employs computational modeling and artificial intelligence to conduct virtual experiments on a vast array of potential biomanufacturing processes. By analyzing experimental data, it provides actionable recommendations that enhance yield, reduce costs, and improve overall sustainability. This innovative approach allows biomanufacturers to accelerate their research and development efforts, facilitating a faster and more efficient path to market for their products.

New Wave Biotech specializes in developing software that optimizes downstream processes for synthetic biology products, particularly in the alternative protein sector. The company's platform employs computational modeling and artificial intelligence to conduct virtual experiments on a vast array of potential biomanufacturing processes. By analyzing experimental data, it provides actionable recommendations that enhance yield, reduce costs, and improve overall sustainability. This innovative approach allows biomanufacturers to accelerate their research and development efforts, facilitating a faster and more efficient path to market for their products.

Dia Beta Labs is a biotechnology company dedicated to improving the lives of individuals with metabolic diseases. It operates from Ulster, where it has access to advanced facilities and a network of experts. The company's focus is on developing therapeutic agents to address the decline of pancreatic health in patients, with the goal of achieving more sustainable and effective weight loss than current options. Its discovery platform uses industry-standard methodologies and models to identify and advance lead molecules for animal research.

Keltic Pharma Therapeutics enhances drug discovery through innovative scientific research, resulting in a healthier future.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Concert Bio is a company that specializes in optimizing microbial communities to enhance the productivity of biotech businesses. It has developed a comprehensive platform that integrates monitoring and analytics to provide insights into microbial ecosystems. By offering targeted interventions, Concert Bio enables organizations to effectively control and improve their microbiomes, ultimately driving better performance in their operations.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.

Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases. Utilizing a research and development platform that leverages insights into the role of activated fibroblast populations in disease, the company aims to create therapeutics that target fibroblast-mediated effects on immune cells. This approach is designed to enhance the medical industry's ability to combat and potentially cure rare and life-threatening conditions. Through its work, Mestag Therapeutics seeks to contribute meaningful advancements in the treatment landscape for these challenging diseases.

Lentitek is a biotechnology company focused on developing gene and gene-modified cell therapies, particularly aimed at treating cancer. The company is dedicated to enhancing the accessibility of innovative cures by increasing the yield of lentiviral vectors, which are critical for gene therapy applications. Lentitek employs a proprietary method that utilizes a novel promoter to significantly boost lentiviral production, potentially increasing yields by tenfold or more. This innovative approach not only improves the efficiency of lentivirus production but also aims to reduce overall production costs for healthcare providers, thereby facilitating broader availability of advanced therapeutic options for patients.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, a group of rare genetic disorders affecting the brain's white matter. The company aims to disrupt existing treatment practices by creating a therapy that addresses the root cause of these diseases, specifically targeting the mutated TUBB4a gene implicated in TUBB4a Leukodystrophy. By leveraging groundbreaking research, SynaptixBio is dedicated to providing potentially curative options for patients suffering from this acute subset of leukodystrophies. The company also maintains an online platform to engage with customers and address inquiries, ensuring transparency and accessibility of information about their advancements.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

BiVictriX Therapeutics Ltd. is a UK-based company focused on drug discovery and development, specializing in bispecific antibody drug conjugates aimed at addressing unmet needs in blood cancer treatment. Established in 2016 and located in Alderley Edge, the company employs its proprietary Bi-Cygni technology to create innovative therapeutics, particularly for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX's expertise encompasses oncology, hematological malignancies, immunotherapy, and antibody research, positioning it as a key player in the development of advanced biotherapeutics and drug development initiatives.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

Fuse Diagnostics focuses on manufacturing diagnostic products that deliver lab-quality information across various sectors. The company aims to provide innovative and cost-effective testing solutions that ensure laboratory accuracy for applications in food and water testing, bioprocessing, and cell biology research. By offering low-cost test kits equipped with integrated readout technology, Fuse Diagnostics enables businesses to obtain rapid and reliable results, thereby enhancing the accessibility and efficiency of diagnostic testing.

AgriSound is an agri-tech company that specializes in advanced sound analysis for monitoring insect activity, particularly focusing on pollinators. The company has developed a pollination management platform that utilizes sound, environmental, and vision technology sensors to monitor and predict pollinator behavior across agricultural estates. This platform enables users, including beekeepers, farmers, and researchers, to assess hive status in near real-time through the use of predictive algorithms. By providing insights into insect activity and environmental changes affecting pollination, AgriSound's technology allows for remote management of beehives and supports timely decision-making. This innovation aims to enhance agricultural operations and promote biodiversity by suggesting appropriate actions to maintain optimal pollination conditions.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.

BSF Enterprise is focused on advancing biotechnology solutions through a strategic approach of acquiring businesses within the biotech, marketing, and e-commerce sectors. The company specializes in cell-based tissue engineering, which enables the development of lab-grown products such as cultured meat, lab-grown leather, human corneas, collagen, and skin substitutes. By leveraging these innovative technologies, BSF Enterprise aims to facilitate sustainable solutions across multiple industries, contributing to significant advancements in the field of biotechnology.

Presymptom Health is a medtech company that specializes in developing clinical decision support algorithms and diagnostic tests aimed at early illness detection. The company focuses on pre-symptomatic diagnostics, allowing for the identification of conditions such as sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health's innovations aim to enhance critical care outcomes and improve patient management. Through its portfolio of blood tests and algorithms, the company seeks to transform the way healthcare providers approach patient care, ultimately contributing to better health outcomes and potentially saving lives.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Aelius Biotech specializes in creating advanced models of the mucosal surfaces of the human body. The company focuses on developing systems that simulate the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract. Aelius Biotech's model gut system allows healthcare industry participants to simulate essential processes such as digestion, mucus permeation, and epithelial absorption. The company provides a range of testing services, including in vitro and in vivo assessments, simple lab assays, and integrated model gut testing across the aerodigestive tract. Additionally, Aelius Biotech conducts human trials, aiding healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

SökerData is a biotechnology company specializing in data analysis solutions for disease-related datasets. It has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across different demographic groups. The platform offers tools for interpreting large datasets, supporting early drug discovery, and aiding researchers in understanding the impact of biomarkers on diverse populations, thereby facilitating informed decision-making and advancing disease outcome understanding.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

PulmoBiomed is a developer of innovative sampling technology that offers a non-invasive method for clinicians and researchers to collect biological samples. The company's primary product is a passive fluid aerosol sampler designed to capture exhaled breath condensate and environmental particles, effectively segregating them by size. This technology addresses critical challenges in sample collection, such as preventing contamination and loss, while ensuring the generation of highly reproducible data with digital molecular precision. By focusing on metabolomic profiling and biological agent capture, PulmoBiomed aims to enhance the accuracy and reliability of respiratory diagnostics and research.

Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Cellcraft is a cultivated meat start-up based in Cambridge, focused on providing a scalable manufacturing platform for cultivated meat production. The company offers a comprehensive system that includes raw materials, hardware, software, and bioprocesses, enabling food producers to create their own cultivated meats on a commercial scale. This approach allows for customization to meet local tastes and specifications while addressing significant challenges related to food security and sustainability. By empowering producers to manufacture cultivated meats locally, Cellcraft aims to democratize access to sustainable food options and contribute to solutions for global sustainability and health issues.

CellRev is a biotechnology company specializing in innovative bioprocessing technologies aimed at improving cell manufacturing for various applications, including cultured meat, cell therapy, and biologics. The company's proprietary technology enables a shift from traditional batch processing to continuous processing of adherent cells, significantly enhancing yield while reducing operating costs and capital expenditures. CellRev's unique cell detachment process, combined with a specially designed bioprocess, addresses critical challenges in manufacturing, such as cell aggregation, clumping, and detachment. This approach allows cell-based vaccine and therapy developers to streamline their production processes, eliminate serum usage, and overcome significant bottlenecks in the industry.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, a group of rare genetic disorders affecting the brain's white matter. The company aims to disrupt existing treatment practices by creating a therapy that addresses the root cause of these diseases, specifically targeting the mutated TUBB4a gene implicated in TUBB4a Leukodystrophy. By leveraging groundbreaking research, SynaptixBio is dedicated to providing potentially curative options for patients suffering from this acute subset of leukodystrophies. The company also maintains an online platform to engage with customers and address inquiries, ensuring transparency and accessibility of information about their advancements.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

PES Technologies specializes in developing advanced technology for soil health analysis. The company has created a microbe sensor that monitors the biological properties of soil, enabling farmers and agronomists to assess the health of their soil effectively. By analyzing the status of microbial activity, the sensor provides insights into long-term changes in soil health resulting from agricultural practices. This innovative tool equips users with the necessary data to make informed decisions regarding soil management, ultimately enhancing agricultural productivity and sustainability.

PES Technologies specializes in developing advanced technology for soil health analysis. The company has created a microbe sensor that monitors the biological properties of soil, enabling farmers and agronomists to assess the health of their soil effectively. By analyzing the status of microbial activity, the sensor provides insights into long-term changes in soil health resulting from agricultural practices. This innovative tool equips users with the necessary data to make informed decisions regarding soil management, ultimately enhancing agricultural productivity and sustainability.

Beta Bugs is an insect genetics company focused on developing high-performance breeds of Black Soldier Fly for insect farmers. The company's primary mission is to enhance the productivity of the insect protein sector, making it competitive with traditional feed ingredients such as fishmeal and soymeal. To achieve this, Beta Bugs operates a breeding program called HiPer-Fly® and runs an egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By leveraging biotechnology and breeding techniques, Beta Bugs aims to establish a sustainable protein source that converts food waste into high-quality protein for use in livestock, aquaculture, and pet feed, thereby providing an alternative to conventional feed sources. The company is headquartered at the Easter Bush Campus, collaborating with the Roslin Institute, a leader in animal genetics.

Pathios Therapeutics Limited is an early-stage drug discovery company based in Oxford, United Kingdom, founded in 2017. The company is dedicated to developing therapies for autoimmune diseases and cancer, focusing on small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to mitigate the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, which is often stimulated by the acidic microenvironment present in tumors. By employing a rigorous scientific approach that includes insights from human genetics and advanced cellular immunology, Pathios aims to generate novel therapeutics that can address advanced solid tumors and other significant medical needs in immuno-oncology.

Carbogenics Ltd is a company based in Edinburgh, United Kingdom, specializing in the development and production of sustainable fertilizers and bio-additives. Established in 2016, Carbogenics has created an innovative process that transforms disposable coffee cups and other non-recyclable paper waste into a carbon-rich material, known as CreChar. This product serves as a carbon additive that enhances biogas production in anaerobic digestion and improves plant growth, ultimately benefiting farmers by increasing crop yields and profitability. In addition to its product offerings, Carbogenics also provides consultancy and analytical services to operators in the anaerobic digestion and wastewater treatment sectors, addressing customer inquiries through various communication channels.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

Intellegens specializes in applying artificial intelligence and machine learning to enhance innovation in various fields, including materials, chemicals, and manufacturing. The company’s flagship software, Alchemite™, originated from research at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional methods often struggle. By utilizing Alchemite™, users can conduct analyses through a user-friendly web interface and leverage advanced graphical tools, which streamline the integration of AI into existing workflows and tools. This capability allows clients to achieve significant improvements, such as reducing the number of required experiments by up to 90%, thereby saving time and costs. Intellegens has successfully implemented its technology in diverse applications, including drug discovery, materials development, and manufacturing processes, enabling clients to extract greater value from incomplete datasets.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.

Concert Bio is a company that specializes in optimizing microbial communities to enhance the productivity of biotech businesses. It has developed a comprehensive platform that integrates monitoring and analytics to provide insights into microbial ecosystems. By offering targeted interventions, Concert Bio enables organizations to effectively control and improve their microbiomes, ultimately driving better performance in their operations.

Metalchemy is a nanotechnology company focused on developing innovative products and bioplastics derived from green nanomaterials. The company specializes in bio-nanotechnology that addresses food waste by transforming it into usable nanomaterials. Through its advancements, Metalchemy aims to make green nanotechnology accessible to a wider audience, contributing to a healthier and more sustainable future while actively tackling the climate crisis.

NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn Biotechnologies is a biotechnology company focused on innovating wound care solutions through its Heals device, which offers a contactless method for treating chronic and complex wounds. The company has developed advanced applicators that utilize electrical voltages to extrude fine fibers from various fluids, creating wound dressings that can be made from synthetic or natural materials. These dressings can be enhanced with or without active ingredients and are designed to deposit non-woven meshes for effective Advanced Tissue Repair (ATR). Through this technology, Corryn aims to improve the management and healing of chronic wounds, providing a novel approach to wound dressing.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research, promoting more efficient and ethical cell culture experiments. Backed by prominent UK research councils, Peptimatrix brings together experts in matrix biology, cancer science, toxicology, and biomaterial engineering to create reproducible, reliable, and ethical in vitro disease and development models.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

PfBIO is a biotechnology company that discovers and develops natural, bacteria-based products to enhance plant health and protect crops from diseases, providing sustainable alternatives to synthetic agrochemicals. The company's innovative platform involves sourcing bacteria from the environment and selecting those with the ability to combat plant pathogens, improve crop yields, and enrich soil quality.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Autolomous Ltd, founded in 2019 and based in Mayfair, United Kingdom, specializes in developing software solutions for manufacturers of cell and gene therapies. Its flagship platform, autoloMATE®, is a cloud-native system that provides comprehensive support for Advanced Therapies and Vector manufacturing processes. The software facilitates the scheduling of patient cell collections, the transport of these cells to production sites, and the tracking of manufacturing processes to ensure compliance with regulatory standards. It also supports the legal release and timely delivery of patient-specific medicines. The highly configurable platform allows clients to customize workflows and integrates seamlessly with existing systems. Autolomous emphasizes data security by utilizing blockchain technology to maintain the integrity of manufacturing data. The company adheres to strict regulatory guidelines and has achieved several ISO certifications, reflecting its commitment to quality management and environmental standards.

Orthonika Limited, established in 2014 and based in London, United Kingdom, specializes in the development and manufacturing of MenisciKnit, an anatomical meniscus replacement designed to address severe meniscus injuries. These injuries can significantly impair mobility and lead to complications such as osteoarthritis and the need for knee arthroplasty. Current treatment options, including partial meniscectomy and allograft transplantation, often fall short, leaving a significant unmet need in the market. MenisciKnit employs a unique fiber-reinforced material structure that closely mimics the natural meniscus, aiming to restore proper knee biomechanics. This innovative approach not only provides a solution for those with severe meniscus damage but also supports patients in resuming active lifestyles and offers a comprehensive alternative to traditional knee-related treatments.

Hexis Lab is a biotechnology company focused on the research and development of innovative natural skincare solutions tailored for diverse skin types globally. The company utilizes a discovery platform that combines big data cloud computing and in-silico computer modeling to analyze a comprehensive database of plant-derived compounds. This approach allows Hexis Lab to identify effective ingredients aimed at protecting and repairing sun-damaged skin while enhancing overall well-being. By employing proprietary AI techniques, Hexis Lab accelerates the development process for clients in the beauty, skincare, personal care, nutraceuticals, and pharmaceutical sectors, facilitating the identification of novel ingredients and formulation strategies.

ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.

Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Flybox® is an Insect Waste Management (IWM) company delivering innovative insect bioconversion technology and expert support to revolutionise waste management. Flybox® provides tailored IWM solutions for established waste and food businesses, alongside a streamlined breeding and monetisation service that simplifies startup and scaling for new operators. Its modular IWM systems integrate seamlessly with existing waste infrastructure, allowing businesses to transform organic waste streams and byproducts into valuable proteins and fertilisers. With patented technology and a steadfast commitment to circular economy principles, Flybox® is advancing global efforts to reduce landfill dependency, minimise reliance on deforestation-linked soy, and enhance food security. Headquartered in the UK and active internationally, Flybox® is a leader in sustainable waste solutions, driving positive change across agriculture, waste management, and environmental resilience.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

DeepMirror is a software platform that integrates human expertise with artificial intelligence to enhance drug discovery processes. The company specializes in predicting the properties of molecules and their affinity for various targets, thereby streamlining the research and development efforts of biopharmaceutical teams. By employing structured perception and feature fusion techniques, DeepMirror's platform delivers advanced 3D insights while maintaining low power consumption. This capability simplifies the analysis of complex data, ultimately allowing researchers to focus on the most promising drug candidates and conduct fewer experiments, leading to more efficient drug development.

Kelpi is a sustainable biotech start-up focused on bio-refining seaweed to create innovative bioplastic packaging solutions. The company develops a thin bio-plastic coating for paper and cardboard, replacing traditional fossil fuel-based plastics used in packaging for food, beverages, cosmetics, and personal care products. This coating is derived from renewable feedstocks, primarily compostable seaweed, and has been certified as recyclable. By utilizing marine-safe materials, Kelpi aims to provide environmentally friendly alternatives that help eliminate single-use plastics, promoting sustainability in packaging practices.

Elaniti leverages advances in machine learning and DNA sequencing to enhance soil biology insights for farmers and agronomists, facilitating informed decision-making. The company offers a predictive analytics service that links soil biology to essential crop health outcomes, such as yield, disease prevalence, and nutrient content. This approach enables growers to optimize input efficiency, thereby saving time and costs while promoting environmental sustainability. Elaniti's platform addresses the data gap in soil health by employing a combination of physics, microbiology, and biochemistry to improve crop health and yields. By focusing on the soil microbiome, Elaniti supports the transition to regenerative agriculture, emphasizing the importance of beneficial microbial activity and biodiversity. Through its innovative crop prediction insights, Elaniti aims to highlight the value of soil's complex biological makeup and contribute to a data-driven transition towards Net-Zero agriculture.

Lightox specializes in developing advanced molecular tools for imaging, therapeutics, and assay development, focusing on innovative cancer treatments. The company has created a range of light-activated drug compounds designed to selectively target and eliminate tumor cells while minimizing harm to surrounding healthy tissue. Their unique fluorescent probes are smaller than any other products currently available, allowing for versatile applications in research and clinical settings. These probes can function as freely-moving agents that easily integrate into cells, or they can be customized with flexible linkers to meet specific research requirements. Lightox aims to enhance patient outcomes by providing more efficient cancer treatment options.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

Multus is a London-based company established in 2019 that specializes in providing affordable and efficient growth media for the cultivated meat industry. By employing a machine learning approach, Multus develops entirely animal-free growth media tailored specifically for animal cells, helping cultivated meat companies scale their production while maintaining high performance. The company focuses on optimizing growth factor proteins produced by genetically engineered microorganisms, thereby eliminating the environmental drawbacks associated with traditional animal serum-based media. This innovative solution supports the growth of diverse animal cell types and tissues, enabling clients to produce sustainable meat products while minimizing the environmental and economic impacts of conventional meat production.

Concert Bio is a company that specializes in optimizing microbial communities to enhance the productivity of biotech businesses. It has developed a comprehensive platform that integrates monitoring and analytics to provide insights into microbial ecosystems. By offering targeted interventions, Concert Bio enables organizations to effectively control and improve their microbiomes, ultimately driving better performance in their operations.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

Biome Bioplastics specializes in the production of biodegradable and compostable materials designed to replace traditional oil-based polymers. The company offers a range of bioplastics, including high-temperature non-woven fibers, flexible films, and various coating and lamination products. Their innovative processing techniques encompass injection molding, sheet extrusion for thermoforming, vacuum forming, blown film production, and monofilaments. By focusing on environmentally sustainable solutions, Biome Bioplastics aims to meet the growing demand for eco-friendly materials, providing clients with cost-effective options that enhance both environmental and end-of-life performance.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Adamo Foods is a UK-based food technology company focused on developing plant-based whole-cut meats through innovative fermentation techniques and mycelium. The company aims to produce sustainable alternatives to traditional meat products, utilizing precision fermentation to create functional meat proteins. By harnessing fungal mycelium, Adamo Foods offers consumers an efficient, sustainable, and ethical way to enjoy meat-like experiences without sacrificing taste or quality.

aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company's unique approaches target a fundamental control pathway associated with various diseases, enabling the development of treatments that can significantly improve patient outcomes. aTen Therapeutics' antibodies are designed to inhibit cancer cell growth, invasion, and metastasis across multiple tumor models. By combining these antibodies with anti-cancer agents, the company seeks to enhance the efficacy of cancer treatments and provide healthcare professionals with effective tools to improve the lives of cancer patients while protecting against the progression of metastases. The management team possesses extensive experience in the biopharmaceutical industry, emphasizing the company's commitment to advancing medical science and patient care.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. Its offerings include induced pluripotent stem cells, human and multispecies primary cells, and a comprehensive cell culture and analysis package. The company utilizes advanced devices such as micro physiological systems and microfluidic designs to enhance drug discovery. One of its notable projects, "Liver on chip," focuses on liver toxicity testing and incorporates techniques like cellular reprogramming and organ-on-chip technology. Stemnovate also offers services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.